达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化*

doi:10.3969/j.issn.1672-5069.2025.05.010

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (5): 679-682.doi: 10.3969/j.issn.1672-5069.2025.05.010

达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化^*

刘志东, 李文松, 高震, 孙李妍, 丁琪

266300 山东省青岛市胶州中心医院临床药学科(刘志东);外科(李文松,高震);肝胆外科(丁琪);滨州医学院附属烟台山医院药剂科( 孙李妍)

收稿日期:2025-02-28 出版日期:2025-09-10 发布日期:2025-09-19
通讯作者: 丁琪,E-mail:52414551@qq.com
作者简介:刘志东,男,42岁,大学本科,主管药师。E-mail:liuzhidong8888@163.com
基金资助:
*山东省烟台市科技创新发展计划基础研究类项目(编号:2023JCYJ065)

Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C

Liu Zhidong, Li Wensong, Gao Zhen, et al

Department of Pharmacy, LiaozhouCentral Hospital, Qingdao 266300, Shandong Province, China

Received:2025-02-28 Online:2025-09-10 Published:2025-09-19

摘要/Abstract

摘要： 目的应用达拉他韦联合阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎(CHC)患者,观察疗效及其外周血淋巴细胞亚群的变化。方法 2022年1月～2024年7月我院收治的65例初始治疗的基因1b型CHC患者,被随机分为对照组32例和观察组33例,分别给予索磷布韦联合达拉他韦治疗或达拉他韦联合阿舒瑞韦治疗3个月。常规检测血清HCV RNA载量,使用流式细胞仪检测外周血淋巴细胞亚群。考核快速病毒学应答(RVR)、治疗结束时病毒学应答(ETVR)和持续病毒学应答(SVR)。结果观察组RVR、ETVR和SVR分别为84.9%、100.0%和100.0%,对照组则分别为84.4%、100.0%和96.9%,两组无显著性差异(P>0.05);在治疗结束时,观察组血清AST和ALT水平分别为(32.5±5.3)U/L和(39.4±5.9)U/L,与对照组【分别为(33.6±6.2)U/L和(40.5±6.3)U/L】比,无显著性差异(P>0.05);观察组外周血CD4⁺细胞和CD8⁺细胞百分比及CD4⁺/CD8⁺细胞比值分别为(36.4±4.8)%和(24.6±2.4)%及(1.1±0.4),与对照组【分别为(35.2±4.2)%和(24.5±2.5)%及(1.1±0.3)】比,无显著性差异(P>0.05)。结论应用达拉他韦联合阿舒瑞韦治疗初治的基因1b型CHC患者也可获得较为满意的抗病毒效果,还需要长期随访观察。

关键词: 丙型肝炎, 达拉他韦, 阿舒瑞韦, 基因1b型, 初始, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of daclatasvir and asunaprevir combination in the treatment of patients with naïve hepatitis C viral genotype 1b-infected chronic hepatitis C (CHC) and changes of peripheral blood lymphocyte subsets. Methods 65naïve patients with HCV genotype 1b-infected CHC were enrolled in our hospital between January 2022 and July 2024, and were randomly assigned to receive sofosbuviranddaclatasvir in 32 patients in control, or to receive asunaprevir and daclatasvir combination in 33 patients in the observation group for 12 weeks. Serum HCV RNA loads were routinely detected, and peripheral blood lymphocyte subsets were determined by FCM. Rapid virological response (RVR), end of treatment virological response (ETVR) and sustained virologicalresponse (SVR) were evaluated. Results RVR, ETVR and SVRin the observation group were 84.9%, 100.0%and 100.0%, not significantly different as compared to 84.4%, 100.0% and 96.9% in the control (P>0.05); by end of the antiviral regimen, serum AST and ALT levels in the observation group were (32.5±5.3)U/L and (39.4±5.9)U/L, both not significantly different as compared to[(33.6±6.2)U/Land (40.5±6.3)U/L, respectively] in the control (P>0.05); percentages of peripheral bloodCD4⁺ and CD8⁺cells as well as CD4⁺/CD8⁺ cell ratio were (36.4±4.8)% and (24.6±2.4)%, and (1.1±0.4), all not significantly different compared to [(35.2±4.2)%,(24.5±2.5)% and (1.1±0.3), respectively] in the control group (P>0.05). Conclusion Daclatasvir and asunaprevir combination in the treatment of naïve patients with HCV genotype 1b-infected CHC is also efficacious, which needs further clinical long-term follow-up.

Key words: Hepatitis C, Daclatasvir, Asunaprevir, Hepatitis C virus genotype 1b, Naïve, Therapy

刘志东, 李文松, 高震, 孙李妍, 丁琪. 达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2025, 28(5): 679-682.

Liu Zhidong, Li Wensong, Gao Zhen, et al. Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C[J]. Journal of Practical Hepatology, 2025, 28(5): 679-682.

参考文献

[1] 王云云,吴万锋,李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响. 实用肝脏病杂志,2023,26(3):344-347.
[2] Kausar S, Said Khan F, et al. A review: Mechanism of action of antiviral drugs. Int J ImmunopatholPharmacol, 2021,35:20587384211002621.
[3] Sabry N, Kamel AM, Cordie A, et al. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. Expert OpinPharmacother, 2023,24(2):159-170.
[4] Fujii H, Kimura H, Hasebe C, et al. Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open, 2022,6(5):344-352.
[5] Saidakova EV, Korolevskaya LB, Shmagel NG, et al. In HIV-infected immunological non-responders, hepatitis C virus eradication contributes to incomplete normalization of systemic inflammation indexes, but does notlead to rapid CD4⁺ T-Cell count recovery. DoklBiochemBiophys, 2023 ,512(1):274-278.
[6] 中华人民共和国国家卫生和计划生育委员会. WS213-2018丙型肝炎诊断. 临床肝胆病杂志,2018,34(8):1619-1621.
[7] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52.
[8] Abu-Freha N, Mathew Jacob B, Elhoashla A, et al. Chronic hepatitis C: Diagnosis and treatment made easy. Eur J Gen Pract, 2022,28(1):102-108.
[9] 彭亚柏,朱秀云,刘赛云,等. 不同基因型HCV感染患者重叠HBV或HIV感染的病毒学特征.分子诊断与治疗杂志,2020,12(7):861-863,886.
[10] 张珂瓈,童静,李昌平. 接受达拉他韦和阿舒瑞韦治疗的初治基因1b型慢性丙型肝炎患者疗效评价. 实用肝脏病杂志,2024,27(6):840-843.
[11] Butt N, Anoshia, Khan MA, et al. Effectiveness of sofosbuvir and daclatasvir in treatment of hepatitis-C: an experience of tertiary care hospital in Karachi. Pak J Med Sci, 2021,37(7):2014-2019.
[12] Mohamed H, Ghany WAE, Yehia R, et al. Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in egyptian patients with direct-acting antiviral agent treatment failure. ClinExpHepatol, 2022,8(1):36-41.
[13] Liu J, Guo M, Ke L, et al. Cost-effectiveness of elbasvir/grazoprevir for the treatment of chronic hepatitis C: A systematic review. Front Public Health, 2022,10:836986.
[14] Wang R, Zhao S, Du J, et al. A correlation analysis of the serum hepcidin concentrations and viral loads in HCV-infected patients. Am J Transl Res, 2021,13(6):6297-6304.
[15] Tojima H, Kakizaki S, Takakusagi S, et al. Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. Hepatol Res, 2020,50(3):303-312.
[16] 刘雅光,胡连智,董一侠,等. 抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化. 实用肝脏病杂志,2024,27(5):689-692.
[17] 刘雅光,胡连智,董一侠. 达卡他韦和索非布韦治疗初治慢性丙型肝炎患者单核细胞亚群和表型的变化. 肝脏,2024,29(4):440-443.
[18] 林雪松,罗锐,阎飞. 慢性丙型肝炎患者外周血单个核细胞HCV RNA检测及其与机体免疫功能的相关性研究. 实用肝脏病杂志,2005,8(3):136-137.
[19] Takakusagi S, Sato K, Marubashi K, et al. Impact of M2BPGi on the hepatocarcinogenesis after the combination therapy with daclatasvir and asunaprevir for hepatitis C. Biomedicines, 2021,9(6):660.
[20] Xia H, Lu C, Wang Y, et al. Efficacy andsafety of direct-acting antiviral therapy in patients with chronic hepatitis C virus infection: A real-world single-center experience in Tianjin, China. Front Pharmacol, 2020,11:710.
[21] Peña-Asensio J, Calvo H, Torralba M, et al. Gamma-chain receptor cytokines & PD-1 manipulation to restore HCV-specific CD8⁺T cell response during chronic hepatitis C. Cells, 2021,10(3):538.

达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化^*

Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025 年版)[J]. 实用肝脏病杂志, 2025, 28(5): 641-647.
[2]	丛东威, 刘丽娜, 高文娟, 黄超群. 干扰素α-2b联合恩替卡韦与干扰素α-2b联合替诺福韦治疗HBeAg阳性慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 655-658.
[3]	陈文哲, 王清园, 陈天, 许宇文. ApoB基因多态性对接受聚乙二醇干扰素α治疗的HBeAg阳性慢性乙型肝炎患者疗效的影响^*[J]. 实用肝脏病杂志, 2025, 28(5): 659-662.
[4]	袁铃, 姜霞, 孙美杰, 岳冬黎, 张晓玲. 艾米替诺福韦与丙酚替诺福韦挽救治疗低病毒血症的慢性乙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 667-670.
[5]	汤勤, 华忠, 苏麒麟, 陈小林. 艾米替诺福韦联合鳖甲煎丸治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 671-674.
[6]	郝帅, 王梓依, 张心怡, 张粉娜, 苏娜, 贺娜. 常态化随访实施院内丙型肝炎微消除策略效果评价^*[J]. 实用肝脏病杂志, 2025, 28(5): 675-678.
[7]	辛文渊, 李玉薇, 吴君. 达卡他韦联合阿舒瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 683-686.
[8]	张磊, 王亚茹, 李会平, 王帅, 张威, 周正, 张帆. 司美格鲁肽治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床初步研究[J]. 实用肝脏病杂志, 2025, 28(5): 699-702.
[9]	王霞, 段旺旺, 李梦辉. 艾塞那肽联合多烯磷脂酰胆碱治疗酒精性肝炎患者初步疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 715-718.
[10]	刘立华, 尤晓红, 范周红. 多烯磷脂酰胆碱联合水飞蓟素治疗102例药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 723-726.
[11]	朱颖静, 吴洁, 田鑫越, 田巍巍. 内镜下组织胶注射治疗乙型肝炎肝硬化食管胃底静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2025, 28(5): 731-734.
[12]	陈洁, 杨才敏, 彭彩玲, 徐辉. 基于北京PIR分型标准评价恩替卡韦治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 735-738.
[13]	穆亚, 葛乃建, 刘学, 王向东, 徐伟, 杨业发. TACE联合贝伐珠单抗和信迪利单抗治疗不可切除肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 751-754.
[14]	张小昭, 雷凯, 祁亚斌, 金雷, 朱代华. 阿替利珠单抗联合靶向药物和TACE术治疗中晚期原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 759-762.
[15]	徐嘉, 彭炜惟, 尹娜, 杨雨婷. 信迪利单抗联合抗血管内皮生长因子单抗治疗不可手术切除的肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 763-766.